Bailard, Inc. Monte Rosa Therapeutics, Inc. Transaction History
Bailard, Inc.
- $4.2 Billion
- Q2 2025
A detailed history of Bailard, Inc. transactions in Monte Rosa Therapeutics, Inc. stock. As of the latest transaction made, Bailard, Inc. holds 22,500 shares of GLUE stock, worth $222,074. This represents 0.0% of its overall portfolio holdings.
Number of Shares
22,500Holding current value
$222,074% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding GLUE
# of Institutions
112Shares Held
58.3MCall Options Held
56.3KPut Options Held
0-
Nea Management Company, LLC Timonium, MD7.69MShares$75.9 Million2.88% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD6.33MShares$62.4 Million0.0% of portfolio
-
Bvf Inc San Francisco, CA5.66MShares$55.9 Million1.0% of portfolio
-
Versant Venture Management, LLC San Francisco, CA5.65MShares$55.8 Million45.25% of portfolio
-
Baker Bros. Advisors LP New York, NY4.92MShares$48.5 Million0.22% of portfolio
About Monte Rosa Therapeutics, Inc.
- Ticker GLUE
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 46,713,900
- Market Cap $461M
- Description
- Monte Rosa Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. It develops an oral molecular glue degrader for GSPT1, a translational termination factor and degron-containing prot...